HCWB
HCW Biologics Inc.
There isn't enough reported data to score HCWB yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
HCWB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
HCWB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HCWB PE Valuation
HCWB has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HCWB Forward outlook
There aren't enough analyst estimates for HCWB to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HCWB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2025 | -$148.80 | +$33.60 |
| Q4 2024 | -$184.80 | -$16.80 |
| Q3 2024 | -$240.00 | -$108.00 |
| Q2 2024 | -$249.60 | -$124.80 |
| Q1 2024 | -$182.40 | -$62.40 |
| Q4 2023 | -$168.00 | -$67.20 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 182% for HCWB versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
HCWB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $121.7K | +1758% |
| Q1 2026 | $6.5M | +128232% |
| Q4 2025 | $27K | -93% |
| Q3 2025 | $15.6K | -96% |
| Q2 2025 | $6.6K | -99% |
| Q1 2025 | $5.1K | -100% |
| Q4 2024 | $394.8K | -70% |
| Q3 2024 | $426.4K | -50% |
HCWB's revenue is growing: $121,730 last quarter, up 1758% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2601% | +50286 points |
| Q1 2026 | 50% | +38861 points |
| Q4 2025 | -16519% | -15719 points |
| Q3 2025 | -21095% | -20230 points |
| Q2 2025 | -52887% | -50441 points |
| Q1 2025 | -38811% | -38146 points |
| Q4 2024 | -800% | +13 points |
| Q3 2024 | -865% | -270 points |
HCWB's operating margin was −2601% last quarter, up 50286 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HCWB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HCWB on profitability, with a higher operating margin.
HCWB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4M | -$683.8K |
| Q1 2026 | -$1.6M | +$1.9M |
| Q4 2025 | -$3.4M | -$407.2K |
| Q3 2025 | -$3.2M | -$276.4K |
| Q2 2025 | -$3.3M | +$1.6M |
| Q1 2025 | -$3.5M | +$219.7K |
| Q4 2024 | -$2.9M | +$4.7M |
| Q3 2024 | -$3M | +$3.3M |
HCWB has burned cash in almost every quarter: −$12M over the past year, against −$13M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HCWB on cash generation, producing positive trailing cash flow while its opponent burns cash.
HCWB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +280% | +978K shares |
| 1 year | +613% | +1.1M shares |
| 3 years | +788% | +1.2M shares |
| 5 years | +1014% | +1.2M shares |
HCWB has 1M diluted shares, up 613% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HCWB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HCWB Net Leverage
HCWB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HCWB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.8 | Neutral |
| Stochastic | 0.6 | Oversold |
HCWB's weekly RSI is 37 (neutral) and its Stochastic is 1 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HCWB PE vs Healthcare Sector
HCWB has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HCWB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 39% below |
| 20 week MA | $2.39 | 67% below |
| 50 week MA | $4.72 | 83% below |
| 100 week MA | $26.6 | 97% below |
| 200 week MA | $171.4 | 100% below |
HCWB is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HCWB on trend strength, trading above more of its moving averages.
HCWB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $1,245.6 | $600.0 | -52% |
| 2022 | $600.0 | $472.8 | -21% |
| 2023 | $472.8 | $295.2 | -38% |
| 2024 | $295.2 | $100.8 | -66% |
| 2025 | $100.8 | $8.52 | -92% |
| 2026 YTD | $8.52 | $0.80 | -91% |
HCWB has finished every year since 2021 lower, and it's down 91% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HCWB on returns for 2026, with the stronger performance.